Edgewise Therapeutics, Inc. $EWTX Stock: Alps Advisors Inc. Boosts Holdings

Key Points

• Alps Advisors increased its Edgewise Therapeutics stake by 32.2% in the third quarter, adding 35,069 shares to reach 143,864 shares, valued at about $5.84 million.
• Reports of potential takeover interest have emerged as a near-term catalyst for EWTX shares, but no deal has been confirmed.
• The FDA gave favorable feedback on EDG-7500’s Phase 3 plan for hypertrophic cardiomyopathy; the STRATUS-HCM study is expected to begin in Q4 2026.

Alps Advisors Inc. lifted its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 32.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 143,864 shares of the company's stock after purchasing an additional 35,069 shares during the quarter. Alps Advisors Inc. owned about 0.13% of Edgewise Therapeutics worth $5,841,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parallel Advisors LLC raised its holdings in shares of Edgewise Therapeutics by 64.9% in the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock worth $33,000 after buying an additional 406 shares during the last quarter. KBC Group NV purchased a new stake in Edgewise Therapeutics during the 1st quarter valued at about $49,000. Sterling Capital Management LLC increased its holdings in shares of Edgewise Therapeutics by 840.2% in the third quarter. Sterling Capital Management LLC now owns 2,360 shares of the company's stock valued at $96,000 after purchasing an additional 2,109 shares during the period. GAMMA Investing LLC increased its holdings in shares of Edgewise Therapeutics by 26.5% in the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock valued at $108,000 after purchasing an additional 559 shares during the period. Finally, Strs Ohio acquired a new position in shares of Edgewise Therapeutics in the first quarter valued at about $217,000.

Edgewise Therapeutics News Summary

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EWTX. The Goldman Sachs Group raised their price objective on Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Raymond James Financial reiterated an "underperform" rating and issued a $85.00 target price on shares of Edgewise Therapeutics in a research report on Thursday. Evercore reiterated an "outperform" rating and issued a $55.00 price target on shares of Edgewise Therapeutics in a report on Monday, July 20th. HC Wainwright reissued a "buy" rating on shares of Edgewise Therapeutics in a research report on Wednesday, October 14th. Finally, Wall Street Zen raised shares of Edgewise Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, October 4th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Edgewise Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $52.83.

Insider Buying and Selling

In other news, General Counsel John Moore sold 5,016 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $43.82, for a total transaction of $219,801.12. Following the sale, the general counsel owned 17,697 shares of the company's stock, valued at $775,482.54. This trade represents a 22.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total transaction of $784,973.28. Following the sale, the chief executive officer directly owned 52,488 shares in the company, valued at $2,292,675.84. This trade represents a 25.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 38,329 shares of company stock valued at $1,675,529. Insiders own 21.30% of the company's stock.

Edgewise Therapeutics Stock Performance

Shares of EWTX opened at $45.04 on Monday. The business's 50-day moving average is $40.86 and its two-hundred day moving average is $36.54. The company has a market capitalization of $4.93 billion, a P/E ratio of 5.50 and a beta of 0.39. Edgewise Therapeutics, Inc. has a fifty-two week low of $16.70 and a fifty-two week high of $48.51.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $10.18. Analysts forecast that Edgewise Therapeutics, Inc. will post 5.43 EPS for the current year.

Edgewise Therapeutics Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions.

Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.

Want to see what other hedge funds are holding EWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.